Wuhan Langlai Pharmaceutical

Wuhan Langlai Pharmaceutical is a clinical-stage biopharmaceutical company based in Wuhan, China, focused on the discovery and development of innovative small molecule drugs. The company targets therapeutic areas with significant unmet medical needs, particularly respiratory diseases, metabolic disorders, and chronic pain. Its lead clinical programs include QR004, a selective P2X3 receptor antagonist for refractory chronic cough, and QR001, a URAT1 inhibitor for the treatment of gout and hyperuricemia. Langlai utilizes an integrated drug discovery platform to advance its pipeline, which features several candidates in various stages of clinical and preclinical development. The company aims to provide high-quality, affordable innovative medicines to patients globally. It is headquartered in the Wuhan National Bio-industry Park, also known as Biolake.